Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

APG-2449

Small molecule · Inhibitor of ALK, FAK (PTK2) and ROS1 · developed by Ascentage Pharma Group

Phase 1 Most advanced trial

AAPG Developer

2 Registered trials

What is APG-2449?

APG-2449 is an orally available kinase inhibitor that selectively binds to and inhibits ALK, FAK, and ROS1. It disrupts ALK-, FAK-, and ROS1-mediated signal transduction pathways to inhibit tumor cell growth in ALK-, FAK-, and ROS1-overexpressing tumors. It is studied in non-small cell lung cancer, esophageal cancer, ovarian cancer, and mesothelioma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: APG -2449
Drug type: Small molecule
Targets: ALK, FAK (PTK2), ROS1
Mechanism: Inhibitor of ALK, FAK (PTK2) and ROS1
Pathways: ALK-mediated signal transduction, FAK-mediated signal transduction, ROS1-mediated signal transduction, tumor angiogenesis
Therapy area: Oncology
Developer: Ascentage Pharma Group Inc. (AAPG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 8L976E3N4N

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06687070	Phase 1	Platinum-resistant Recurrent Ovarian Cancer	Recruiting	AAPG
NCT03917043	Phase 1	Advanced Solid Cancer	Recruiting	AAPG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid CancerAdvanced Solid TumorEsophageal CancerMalignant Pleural MesotheliomaNon Small Cell Lung CancerOvarian CancerPlatinum-resistant Recurrent Ovarian Cancer

Other drugs acting on ALK / PTK2 / ROS1

Alectinib FDA approved Repotrectinib FDA approved Taletrectinib FDA approved Zidesamtinib FDA approved NVL-655 Phase 3

More from Ascentage Pharma Group

Alrizomadlin Phase 1/2 APG-3288 Phase 1 APG-5918 Phase 1 Dasminapant Phase 1/2 Lisaftoclax Phase 3 Olverembatinib Phase 3 Pelcitoclax Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AAPG page.

Follow AAPG, the company behind APG-2449

See AAPG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AAPG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z